Normal view MARC view ISBD view

Linear IgA Disease of the Gingiva Following Nivolumab Therapy. - 2019

Available online from MWHC library: 2000 - present

Immunotherapy has advanced the treatment of solid organ malignancies. Although generally well tolerated, treatment with immune checkpoint inhibitors can be complicated by immune-related adverse events, some of which are relatively uncommon. We report the first case of gingival linear immunoglobulin A disease related to treatment with an antiprogrammed cell death protein 1 antibody. A 73-year-old male with advanced non-small cell lung cancer achieved a durable response to nivolumab monotherapy. After 1 year of treatment, he developed gingival swelling and pain. Biopsy revealed linear immunoglobulin A disease of the gingiva which was effectively treated with systemic steroids. Ongoing vigilance for immune-mediated toxicity is paramount during and after treatment with immune checkpoint inhibitors.


English

ISSN: 1524-9557

Standard No.: 10.1097/CJI.0000000000000288 [doi]

Subjects--Topical Terms:
*Antineoplastic Agents, Immunological/ae [Adverse Effects]
*Gingival Diseases/et [Etiology]
*Immunoglobulin A
*Nivolumab/ae [Adverse Effects]
Aged
Carcinoma, Non-Small-Cell Lung/dt [Drug Therapy]
Humans
Lung Neoplasms/dt [Drug Therapy]
Male

Subjects--Geographic Terms:
MedStar St Mary's Hospital
MedStar Washington Hospital Center

Index Terms--Occupation:
Otolaryngology

Index Terms--Function:
Journal Article